» Articles » PMID: 36574369

Humanistic Burden of Problem Joints for Children and Adults with Haemophilia

Overview
Journal Haemophilia
Specialty Hematology
Date 2022 Dec 27
PMID 36574369
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: The "problem joint" (PJ) concept was developed to address patient-centric needs for a more holistic assessment of joint morbidity for people with haemophilia (PwH).

Aim: To quantify the humanistic burden of PJs in PwH to further support validation of the PJ outcome measure.

Methods: Multivariable regression models evaluated the relationship between PJs and health-related quality of life (HRQoL, EQ-5D-5L) and overall work productivity loss (WPL) using data from the 'Cost of HaEmophilia: a Socioeconomic Survey' population studies (adults: CHESS II, CHESS US+; children/adolescents: CHESS-Paeds). Covariates included were haemophilia severity, age, comorbidities and education.

Results: The CHESS II sample included 292 and 134 PwH for HRQoL and WPL analyses, mean age 38.6 years (39% ≥1 PJ, 61% none). CHESS US+ included 345 and 239 PwH for HRQoL and WPL, mean age 35 years (43% ≥1 PJ, 57% none). CHESS-Paeds included 198 PwH aged 4-17 (HRQoL only), mean age 11.5 years (19% ≥1 PJ, 81% none). In CHESS II and CHESS US+, presence of PJs was associated with worse HRQoL (Both p < .001). Few CHESS-Paeds participants had PJs, with no significant correlation with HRQoL. In CHESS II, upper body PJs were significantly correlated to WPL (p < .05). In CHESS US+, having ≥1 PJ or upper and lower body PJs were significantly correlated to WPL (vs. none; both p < .05).

Conclusion: This study has shown a meaningful burden of PJs on PwH, which should be considered in clinical and health policy assessments of joint health.

Citing Articles

An assessment of burden associated with problem joints in children and adults with moderate or severe haemophilia A: analysis of the CHESS-Paediatrics and CHESS II cross-sectional studies.

McLaughlin P, De la Corte-Rodriguez H, Burke T, Nissen F, Aizenas M, Moreno K Orphanet J Rare Dis. 2025; 20(1):18.

PMID: 39806420 PMC: 11726912. DOI: 10.1186/s13023-024-03514-1.


Distribution and predictors of haemophilia-related costs in the United Kingdom: analysis of the CHESS I and CHESS II burden of illness studies.

Woollacott I, Chhabra A, Burke T, Brownrigg J, Richardson L, Ferri Grazzi E BMC Health Serv Res. 2024; 24(1):1437.

PMID: 39563410 PMC: 11577900. DOI: 10.1186/s12913-024-11850-y.


Assessment of joint health in patients receiving prophylaxis for haemophilia A: a cross-sectional survey in five European countries.

De la Corte-Rodriguez H, Bystricka L, Ball N, Olsen S, Golden K, Hakimi Z BMJ Open. 2024; 14(9):e082204.

PMID: 39260833 PMC: 11409238. DOI: 10.1136/bmjopen-2023-082204.


Economic and Humanistic Burden of Moderate and Severe Hemophilia A and B in Spain: Real-World Evidence Insights from the CHESS II Study.

Peral C, De Lossada Juste A, Lwoff N, Espinoza-Camac N, Casado M, Burke T J Health Econ Outcomes Res. 2024; 11(1):122-133.

PMID: 38721331 PMC: 11078526. DOI: 10.36469/001c.92369.


Six-Year, Real-World Use of Prophylaxis with Recombinant Factor IX-Albumin Fusion Protein (rIX-FP) in Persons with Hemophilia B: A Single-Center Retrospective-Prospective Study.

Coppola A, Rivolta G, Quintavalle G, Matichecchia A, Riccardi F, Rossi R J Clin Med. 2024; 13(5).

PMID: 38592343 PMC: 10933977. DOI: 10.3390/jcm13051518.